SALICYLIC ACID
RxNorm 1095689· TOPICAL
Acella Pharmaceuticals, LLC
Indications and usage
INDICATIONS AND USES: Salicylic Acid, 27.5% Wart Remover is indicated for the topical treatment and removal of common warts and plantar warts.
Dosage and administration
DOSAGE AND ADMINISTRATION: Prior to application of Salicylic Acid, 27.5% Wart Remover, soak wart in warm water for five minutes. Remove any loosened tissue by gently rubbing with a brush, wash cloth or emery board. Dry thoroughly. Using the brush applicator supplied, apply twice to entire wart surface, allowing the first application to dry before applying the second. Treatment should be once or twice a day and should continue as directed by physician. Be careful not to apply to surrounding skin. Clinically visible improvement will normally occur during the first or second week of therapy. Maximum resolution may be expected after four to six weeks of use.
Contraindications
CONTRAINDICATIONS: Salicylic Acid, 27.5% Wart Remover should not be used by diabetics or patients with impaired blood circulation. Salicylic Acid, 27.5% Wart Remover should not be used on moles, birthmarks, unusual warts with hair growing from them or warts on the face.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- drug ineffective13,784
- dry skin12,765
- erythema12,317
- acne11,761
- skin burning sensation11,555
- skin irritation7,729
- skin exfoliation5,757
- inappropriate schedule of product administration4,808
- rash4,754
- overdose3,777
- pain of skin3,498
- pruritus3,462
- hypersensitivity2,980
- condition aggravated1,657
- underdose1,481
- urticaria1,284
Adverse reactions (label)
ADVERSE REACTIONS: A localized irritant reaction may occur if Salicylic Acid, 27.5% Wart Remover is applied to the normal skin surrounding the wart. Any irritation may normally be controlled by temporarily discontinuing use and by applying the medication only to the wart site when treatment is resumed.
View more: Full FDA label on DailyMed →Label effective 20260424